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Evidence for Extrarenal Production of
1a,25-Dihydroxyvitamin D in Man
PHILLIP W. LAMBERT, PAULA H. STERN, RICHARD C. AVIOLI,
NEWTON C. BRACKETT, RUSSELL T. TURNER, ANNE GREENE, IRENE Y. Fu, and
NORMAN H. BELL, Veterans Administration Medical Center and Department
of Medicine, Case Western Reserve University Medical School, Cleveland,
Ohio 44106; Department of Pharmacology, Northwestern University Dental
and Medical Schools, Chicago, Illinois 60611; Veterans Administration
Medical Center and Departments of Medicine and Pharmacology, Medical
University of South Carolina, Charleston, South Carolina 29403
A B S T R A C T Recent studies provide evidence for
extrarenal production of la,25-dihydroxyvitamin D
[la,25(OH)2D]. To investigate this possibility, serum
vitamin D, 25-hydroxyvitamin D (25-OHD), 24,25-
dihydroxyvitamin D [24,25(OH)2D], and la,25(OH)2D
were measured in eight adult anephric subjects. All
were undergoing hemodialysis and three of them were
receiving vitamin D, 50,000 or 100,000 U/d. Serum
vitamin D was elevated in two of the patients given
vitamin D and was abnormally low in the others. Mean
serum 25-OHD was increased in patients given vita-
min D (94.0±7.6 ng/ml) and was normal in the others
(16.4±0.9 ng/ml, P < 0.001). Mean serum 24,25(OH)2D
was normal in patients given vitamin D (1.38±0.27
ng/ml) and was low in the others (0.25±0.08 ng/ml,
P < 0.001). Serum 24,25(OH)2D correlated signifi-
cantly with serum 25-OHD (r = 0.848, P < 0.01). Mean
serum la,25(OH)2D determined by receptor assay was
5.8±1.9 pg/ml in patients who were not given vitamin
D and was 14.1±0.6 in those who were given vitamin
D (P < 0.001). Serum la,25(OH)2D correlated signif-
icantly with serum 25-OHD (r = 0.911, P < 0.01).
Mean serum la,25(OH)2D, measured by bioassay, was
8.3±1.9 pg/ml in patients who were not given vitamin
D and was 15.9±2.4 pg/ml in those who were given
vitamin D (P < 0.05). There was a significant corre-
lation between the values for serum la,25(OH)2D ob-
tained with the two methods (r = 0.728, P < 0.01). The
results (a) provide evidence in man for extrarenal pro-
duction of both 24,25(OH)2D and, by two independent
assays, of la,25(OH)2D, and (b) indicate that serum
Address reprint requests to Dr. Bell, Veterans Adminis-
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values of the two dihydroxy metabolites of vitamin D
in anephric subjects vary with the serum concentration
of the precursor 25-OHD.
INTRODUCTION
It is widely accepted that la,25-dihydroxyvitamin D
[1a,25(OH)2D]1 is produced only by the kidneys. A
number of laboratories, including our own, reported
undetectable values for serum la,25(OH)2D in ane-
phric individuals by receptor assay (1-5), radioim-
munoassay (6, 7), and bioassay (8). In one study, low
but detectable values were found in three patients by
receptor assay. In this study, it was not clear whether
the findings represented extrarenal production, intake
of exogenous 1,25(OH)2D, or an artefact (9). Recent
evidence suggests extrarenal synthesis of the metabo-
lite: conversion of [3H]25-hydroxyvitamin D3 (25-OHD)
to [3H]la,25(OH)2D3 by cultured human bone cells
(10) and by cultured chick calvarial cells (11) was dem-
onstrated. The structure of the la,25(OH)2D3 bio-
logically synthesized by the chick calvarial cells was
verified by mass spectroscopy (Dr. Turner, unpub-
lished observations). Also, a patient with sarcoid was
reported in whom hypercalcemia, increased circulat-
ing la,25(OH)2D, and suppressed serum immuno-
reactive parathyroid hormone (PTH) were present af-
ter bilateral nephrectomy (12). The serum calcium
varied directly with the serum la,25(OH)2D. Hyper-
calcemia and the elevated serum la,25(OH)2D in this
1 Abbreviations used in this paper: 1,25(0H)2D, 1,25-di-
hydroxyvitamin D; 24,25(OH)2D, 24,25-dihydroxyvitamin
D; 25-OHD, 25-hydroxyvitamin D; PTH, parathyroid hor-
mone.
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patient returned to normal upon treatment with glu-
cocorticoids.
In view of these findings, we measured serum
la,25(OH)2D in a group of anephric individuals. Ev-
idence obtained with receptor assay (5) and bioassay
(8) is presented, indicating that low but detectable
serum values of the metabolite are regularly present
in the absence of the kidneys. Further, the values are
higher in patients on treatment with vitamin D2, and
there is a positive correlation between serum 25-OHD
and serum la,25(OH)2D in anephric subjects.
METHODS
Eight anephric patients, two men and six women, were stud-
ied. They ranged in age from 33 to 48 yr. All of them were
on treatment with hemodialysis. Three of them were studied
during admission to either the Medical University Hospital
or the Charleston Veterans Administration Medical Center.
The other five were studied while they were treated as out-
patients in the Dialysis Clinic. At the time of evaluation,
none of them had received blood transfusions for at least 2
d. None were on treatment with la-hydroxyvitamin D3,
la,25(OH)2D3, or dihydrotachysterol.
Blood samples were obtained in the fasting state for de-
termination of serum calcium, phosphorus, creatinine, im-
munoreactive PTH, vitamin D, 25-OHD, 24,25-dihydroxy-
vitamin D [24,25(OH)2D], and la,25(OH)2D. Serum calcium
(13), phosphorus (14), and creatinine (15) were determined
by automated methods. Serum immunoreactive PTH was
measured by radioimmunoassay with antiserum from chicken
77125 at a final concentration of 1:10,000 (16). Normal val-
ues are 0.28±0.12 ng/ml (mean±SD) in a group of 85 normal
adults between the ages of 21 and 49 yr (16). Serum vitamin
D, 25-OHD, and 24,25(OH)2D were assayed after extraction
and chromatography by the protein binding method with
normal rat serum (5, 17). Normal values are 2.6±0.8 ng/ml
(mean+SD, n = 21) for vitamin D, 27.7±6.4 ng/ml (n = 95)
for 25-OHD, and 1.4±0.6 ng/ml (n = 85) for 24,25(OH)2D
(5). Serum la,25(OH)2D was measured by assay with the
cytosol receptor from chick intestinal mucosa after extrac-
tion and chromatography (5, 17). Normal values are 34.2±7.4
pg/ml (n = 65). Serum la,25(OH)2D was also determined
by bioassay (8). Normal values are 32.0±11.3 pg/ml.
Student's t test was used to determine the significance of
differences of unpaired samples. Correlation coefficient and
Student's t test were done with a calculator (model 9815 A,
Hewlett-Packard Co., Palo Alto, Calif.).
RESULTS
Clinical findings in the patients are summarized in
Table I. All were undergoing treatment with chronic
hemodialysis and three of them were being treated
with vitamin D2. Each had marked elevation of serum
creatinine. Patient B had hypocalcemia (with a normal
serum immunoreactive PTH) as a result of parathy-
roidectomy despite a daily intake of 100,000 U of vi-
tamin D2. Two patients were hypercalcemic. In patient
A serum immunoreactive PTH was normal, and in
patient H it was increased. Serum immunoreactive
PTH was abnormally elevated in each of the other
patients, all of whom had a normal serum calcium.
Serum phosphorus was normal in four patients as a
result of treatment with aluminum gels and was ele-
vated in each of the other patients.
The values for circulating vitamin D and its metab-
olites are summarized in Table II. Serum vitamin D
was elevated in two of the three patients on treatment
with vitamin D and was abnormally low in the third
individual. It was abnormally reduced in each of the
other five patients. Mean serum 25-OHD was increased
in patients given vitamin D (94.0±7.6 ng/ml, ±1 SE)
and was normal in those who were not given the vi-
tamin (16.4±0.9 ng/ml, P <0.001). Mean serum
24,25(OH)2D was normal in patients taking vitamin
D (1.38±0.27 ng/ml) and was significantly reduced in
those who were not given the vitamin (0.25±0.08 ng/
ml, P < 0.001). There was a positive correlation be-
tween serum 25-OHD and serum 24,25(OH)2D (r =
0.848, P < 0.01). Mean serum la,25(OH)D2, measured
TABLE I




Patient Age Sex Ca P Creat PTH dialysis roidectomy Vitamin D2
yr mg/dl mg/di mg/dl ng/ml Uld
A 48 F 11.3 5.2 11.8 0.74 + - 100,000
B 46 F 7.4 4.2 12.0 0.44 + + 100,000
C 34 F 9.4 6.4 15.5 1.89 + - -
D 48 M 9.3 3.1 9.4 1.65 + - -
E 45 F 8.4 8.1 17.2 1.38 + - 50,000
F 34 F 10.0 6.2 15.0 2.75 + - -
G 48 M 8.8 3.3 11.6 1.30 + -
H 33 F 11.6 4.1 13.5 2.25 + -
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TABLE II




Patient Vitamin D 25-OHD 24,25(OH)2D a b
ng/mI ng/mL ng/ml pg/ml
At 107.0 89.5 0.56 14.4 14.9
37.5 109.5 1.71 13.1 15.9
Bt 0.41 93.8 1.10 14.7 11.4
0.32 105.9 1.90 14.0 13.3
C 0.81 16.9 0.06 3.2 3.5
0.05 4.2 0.16 3.9 4.9
D 0.05 16.4 0.03 - 7.1
0.09 17.4 0.29 6.4 15.4
Et 10.8 71.2 1.61 14.1 23.8
F 0.18 16.7 0.22 7.7 10.3
G 0.06 16.4 0.46 7.9 -
H 0.20 14.8 0.53 5.6 8.8
Normal
values: 2.6±0.8 27.7±6.4 1.4±0.6 34.2±7.4 32.0±11.3
° a is by receptor assay and b is by bioassay. There was a significant
correlation between the values for the two methods (r = 0.728, P
< 0.01).
t On treatment with vitamin D2 (see Table I).
The interval between samples in patients A-D was 6 mo or greater.
Normal values are given as mean±SD.
by receptor assay, was significantly higher in patients
who were given vitamin D (14.1±0.6 pg/ml) than in
those who were not given the vitamin (5.8±1.9 pg/ml,
P < 0.001). There was a positive correlation between
serum 25-OHD and serum la,25(OH)2D (r = 0.911,
P < 0.01). Mean serum la,25(OH)2D, measured by
bioassay, was similarly higher in patients given
vitamin D (15.9±2.4 pg/ml) than in those who were
not given the vitamin (8.3±1.9 pg/ml, P < 0.05). There
was a significant correlation between the serum values
for la,25(OH)2D with the two methods (r = 0.728, P
< 0.01).
DISCUSSION
Our findings indicate that 24,25(OH)2D and la,-
25(OH)2D are regularly present in the sera of anephric
patients. As regards 24,25(OH)2D, previous results in
anephric subjects were conflicting. Values were re-
ported as being either low (5, 18-20) or undetectable
(20, 21). Our results showing increases in serum
24,25(OH)2D during treatment with vitamin D are
consistent with those recently reported in anephric
pigs (20). The failure to demonstrate detectable serum
values in previous studies may be due to differences
in methods, including sensitivity and accuracy of the
binding assays and recovery after extraction and pu-
rification of serum samples (5).
Previous unsuccessful attempts to demonstrate
la,25(OH)2D in sera from anephric individuals may
have occurred because the quantity of serum used was
inadequate. This was clearly the case in our previously
reported studies (5, 8). These and our present results
were obtained with two quite independent and highly
sensitive assays: one uses the displacement of [3H]-
la,25(OH)2D3 from chick intestinal cytosol receptor
(5, 17) and the second uses the release of 45Ca from
long bones of fetal rats in tissue culture (8). With both
methods, the putative la,25(OH)2D found in the pres-
ent report was purified by extraction and purification
by high pressure liquid chromatography. It is unlikely
that another metabolite with the same chromato-
graphic and biologic properties of la,25(OH)2D was
isolated. In previous studies, these two assay systems
showed a remarkable degree of correlation in their
responses to a wide range of analogues of vitamin D
(22). Our findings, therefore, provide strong evidence
that there are sites other than the kidney for the pro-
duction of la,25(OH)2D in man.
As noted already, evidence for extrarenal produc-
tion of la,25(OH)2D was reported in an anephric pa-
tient with sarcoidosis (12). Synthesis of the metabolite
was demonstrated in cultured human bone cells (10),
cultured chick calvarial cells (11), human decidua (23),
and rat placenta (24).
Under normal circumstances, circulating serum
la,25(OH)2D is closely regulated by serum PTH so
that there is no correlation between the serum 25-OHD
and serum la,25(OH)2D (17). However, in the absence
of PTH (that is, in patients with hypoparathyroidism),
there is positive correlation between serum 25-OHD
and serum la,25(OH)2D (25). In our studies there was
a similar positive correlation in anephric patients, most
of whom had secondary hyperparathyroidism but one
of whom had had a parathyroidectomy. Also, a positive
correlation between serum 25-OHD3 and serum
la,25(OH)2D3 was observed in children with chronic
renal failure who were on treatment with 25-OHD3
when the glomerular filtration rate was !25 ml/min
(26). Further studies are indicated to characterize the
metabolic regulation of human 25-OHD-la-hydrox-
ylases in extrarenal tissue.
All of the patients who were not receiving vitamin
D exhibited low values for circulating vitamin D. Pre-
liminary results suggest impairment in the photopro-
duction of the vitamin in the epidermis of patients
724 Lambert, Stern, Avioli, Brackett, Turner, Greene, Fu, and Bell
who are on chronic hemodialysis (27). We have no
explanation for the low values in one of our patients
who was on treatment with vitamin D.
ACKNOWLEDGMENTS
We thank Virginia Locklair for secretarial assistance and the
laboratory staff of the General Clinical Research Center in
Charleston.
This paper was supported in part by research funds from
the Veterans Administration and by grants AM 11262 and
M01 RR 1070 from the U. S. Public Health Service.
REFERENCES
1. Shephard, R. M., R. L. Horst, A. J. Hamstra, and H. F.
DeLuca. 1979. Determination of vitamin D and its me-
tabolites in plasma from normal and anephric man.
Biochem. J. 182: 55-69.
2. Gray, R. W., J. Lemann, and N. D. Adams. 1979. The
regulation of plasma 1,25(OH)2D concentrations in
healthy adults. In Vitamin D: Basic Research and its
Clinical Application. A. W. Norman, K. Schaefer, D. v.
Herrath, H-G. Grigoleit, J. W. Coburn, H. F. DeLuca,
E. B. Mawer, and T. Suda, editors. Walter De Gruyter,
Hawthorne, N. Y. 545-551.
3. Taylor, C. M., J. Hann, J. St. John, J. E. Wallace, and
E. B. Mawer. 1979. 1,25-Dihydroxycholecalciferol in
human serum and its relationships with other metabo-
lites of vitamin D3. Clin. Chim. Acta. 96: 1-8.
4. Haussler, M. R., M. R. Hughes, J. W. Pike, and T. A.
McCain. 1979. Radioligand receptor assay for 1,25-di-
hydroxyvitamin D: biochemical, physiologic and clinical
applications. In Vitamin D: Basic Research and its Clin-
ical Application. A. W. Norman, K. Schaeffer, D. v.
Herrath, H-G. Grigoleit, J. W. Coburn, H. F. DeLuca,
E. B. Mawer, and T. Suda, editors. Walter De Gruyter,
Hawthorne, N.Y. 473-482.
5. Lambert, P. W., P. B. DeOreo, B. W. Hollis, I. Y. Fu,
D. J. Ginsberg, and B. A. Roos. 1981. Concurrent mea-
surement of plasma levels of vitamin D3 and five of its
metabolites in normal, chronic renal failure, and ane-
phric humans. J. Lab. Clin. Med. 98: 536-548.
6. Bouillon, R., P. DeMoor, E. G. Baggiolini, and M. R.
Uskokovic. 1980. A radioimmunoassay for 1,25-dihy-
droxycholecalciferol. Clin. Chem. 26: 562-567.
7. Clemens, T. L., G. N. Hendy, S. E. Papapoulos, L. J.
Fraher, A. D. Care, and J. L. H. O'Riordan. 1979. Mea-
surement of 1,25-dihydroxycholecalciferol in man by
radioimmunoassay. Clin. Endocrinol. 11: 225-234.
8. Stern, P. H., P. E. Phillips, and T. Mavreas. 1980. Bioas-
say of 1,25-dihydroxyvitamin D in human plasma pu-
rified by partition, alkaline extraction, and high pressure
chromatography. Anal. Biochem. 102: 22-30.
9. Jongen, M. J. M., W. J. F. van der Vijgh, H. J. J. Willems,
and J. C. Netelenbos. 1981. Analysis for 1,25-dihydroxy-
vitamin D in human plasma, after a liquid chromato-
graphic purification procedure, with a modified com-
petitive protein-binding assay. Clin. Chem. 27: 444-450.
10. Howard, G. A., R. T. Turner, D. J. Sherrard, and D. J.
Baylink. 1981. Human bone cells in culture metabolize
25(OH)D3 to 1,25(OH)2D3 and 24,25(OH)2D3. J. Biol.
Chem. 256: 7738-7740.
11. Turner, R. T., E. J. Puzas, M. D. Forte, G. E. Lester,
T. K. Gray, G. A. Howard, and D. J. Baylink. 1980. In
vitro synthesis of la,25-dihydroxycholecalciferol and
24,25-dihydroxycholecalciferol by isolated calvarial cells.
Proc. Natl. Acad. Sci. U. S. A. 77: 5720-5724.
12. Barbour, G. L., J. W. Coburn, E. Slatopolsky, A. W.
Norman, and R. L. Horst. 1981. Hypercalcemia in an
anephric patient with sarcoidosis: evidence for extra-
renal generation of 1,25-dihydroxyvitamin D. N. Engi.
J. Med. 305: 440-443.
13. Baginsky, E. S., S. S. Marie, W. L. Clark, and B. Zak.
1973. Direct microdetermination of calcium. Clin. Chim.
Acta. 46: 49-54.
14. Fiske, C. H., and Y. Subbarow. 1925. The colorimetric
determination of phosphorus. J. Biol. Chem. 66: 375-
400.
15. Folin, O., and H. Wu. 1919. A system of blood analysis.
J. Biol. Chem. 38: 81-110.
16. Wiske, P. S., S. Epstein, N. H. Bell, S. F. Queener, J.
Edmondson, and C. C. Johnston, Jr. 1979. Increases in
immunoreactive parathyroid hormone with age. N.
Engi. J. Med. 300: 1419-1421.
17. Lambert, P. W., B. W. Hollis, N. H. Bell, and S. Epstein.
1980. Demonstration of lack of change in serum 1,Z5-
dihydroxyvitamin D3 in response to parathyroid extract
in pseudohypoparathyroidism. J. Clin. Invest. 66: 782-
791.
18. Horst, R. L., R. M. Shepard, N. A. Jorgensen, and H. F.
DeLuca. 1979. The determination of 24,25-dihydroxy-
vitamin D and 24,26-dihydroxyvitamin D in plasma
from normal and nephrectomized man. J. Lab. Clin.
Med. 93: 277-285.
19. Kano, K., A. Nonada, H. Yoneshima, and T. Suda. 1980.
Serum concentrations of 25-hydroxyvitamin D and
24,25-dihydroxyvitamin D in patients with various types
of renal disease. Clin. Nephrol. 14: 274-279.
20. Horst, R. L., E. T. Littledike, R. W. Gray, and J. L.
Napoli. 1981. Impaired 24,25-dihydroxyvitamin D pro-
duction in anephric human and pig. J. Clin. Invest. 67:
274-280.
21. Taylor, C. M., E. B. Mawer, J. E. Wallace, J. St. John,
M. Cochran, R. G. G. Russell, and J. A. Kanis. 1978. The
absence of 24,25-dihydroxycholecalciferol in anephric
patients. Clin. Sci. Mol. Med. 55: 541-547.
22. Stern, P. H. 1981. A monolog on analogs: in vitro effects
of vitamin D metabolites and consideration of the min-
eralization question. Calcif. Tissue Int. 33: 1-4.
23. Weisman, Y., A. Harrell, S. Edelstein, M. David, Z. Spi-
rer, and A. Golander. 1978. la,25-dihydroxyvitamin Ds
and 24,25-dihydroxyvitamin D3 in vitro synthesis by
human decidua and placenta. Nature (Lond.). 281: 317-
319.
24. Tanaka, Y., B. Halloran, H. K. Schnoes, and H. F.
DeLuca. 1979. In vitro production of 1,25-dihydroxy-
vitamin D3 by rat placental tissue. Proc. Nati. Acad. Sci.
U. S. A. 76: 5033-5035.
25. Lund, B., 0. H. Sorensen, B. Lund, J. E. Bishop, and
A. W. Norman. 1980. Vitamin D metabolism in hypo-
parathyroidism. J. Clin. Endocrinol. Metab. 51: 606-
610.
26. Norman, M. E., and H. Taylor. 1981. Interrelationship
of serum 25-OHD3 and 1,25(OH)2Ds levels in juvenile
renal osteodystrophy during therapy with 25-OHD3.
Calcif. Tissue Int. 33: 40. (Abstr.).
27. Sallman, A. L., A. I. Jacob, B. Hollis, P. Lambert, and
J. J. Bourgoignie. 1981. Impaired photoproduction of
vitamin D in uremia. Abstracts of the 14th Annual Meet-
ing of the American Society of Nephrology. 13A.
Extrarenal la,25-Dihydroxyvitamin D 725
